other material
confidence high
sentiment positive
materiality 0.50
C4 Therapeutics cemsidomide biomarker data positive; 75 µg elranatamab combo declared safe, Phase 1b advances
C4 Therapeutics, Inc.
- Phase 1 cemsidomide + dexamethasone in 62 heavily pre-treated RRMM patients showed coordinated CD8+ T-cell activation and NK-cell reprogramming at the 75 µg and 100 µg doses.
- Phase 1b cemsidomide + elranatamab (ELREXFIO): first two patients showed CD8+ effector memory T-cell expansion (elevated HLA-DR) with no rise in exhaustion markers PD-1, TIM-3, LAG3.
- Safety data review committee declared the 75 µg cemsidomide dose with elranatamab safe after the first six-patient cohort; trial advancing to a 100 µg escalation cohort and a 75 µg expansion cohort.
- Data from all Phase 1b cohorts evaluated are expected in mid-2027; results presented at the 23rd International Myeloma Society Annual Meeting on September 25, 2026.
- CMO Len Reyno said the data reinforce a strategy to establish cemsidomide as a backbone therapy in multiple myeloma for immune-based combinations.